Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Immunitor LLC
With
Immunitor Inc.
Experimental batch of tableted thermostable vaccine obtained from pooled plasma of COVID-19 patients is produced. The goal of this trial is test safety and immunogenicity of once-per-day day administered orally to volunteers for 15 days. Baseline and post-treatment standard safety parameters will be compared. Blood samples from volunteers will be monitored and immunogenicity lab assays will be undertaken to characterize immune response.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Confirmed cases of Covid-19 (all by RT-PCR from same laboratory)
Mild to severe clinical presentation (identified at the time of admission to ward by National Early Warning Score NEWS-2; mild 0-4; severe 5-6)
You may not be if
Unable to take oral medication,
Immunocompromised
Known comorbid condition like hypertension, cardiovascular disease, diabetes mellites, asthma, COPD, cerebrovascular disorder, malignancy of any type, pregnancy,
